Having spent the last eight months integrating Consensus into our oncology department's weekly tumor board workflow, I wanted to share a detailed, real-world account that goes beyond the typical feature list. This isn't a sales pitch; it's a deployment report from the trenches with a team of 10 clinicians (medical, radiation, and surgical oncologists, plus fellows).
Our primary use case is accelerating pre-meeting literature review. Previously, a fellow or resident would manually search and collate recent studies for each complex case. Consensus promised to streamline this, but the devil is in the details.
**Our Implementation & Key Findings:**
* **Prompt Engineering is Non-Negotiable:** The out-of-the-box "summarize" queries were too generic. We developed a structured prompt template that became essential:
* "For a [e.g., metastatic colorectal cancer] patient with [specific mutation, e.g., KRAS G12C] who has progressed on [specific regimen], identify and summarize the most recent (last 3 years) clinical trials and systematic reviews discussing [specific intervention, e.g., triplet chemotherapy vs. immunotherapy combinations]. Focus on progression-free survival and grade 3+ adverse events."
* This specificity cut down irrelevant results by roughly 70% and made the summaries immediately actionable.
* **The "Source Consensus" Metric is a Double-Edged Sword:** While useful for quickly gauging scientific agreement, our team found it sometimes oversimplified nuanced oncology debates. A study showing a 1.5-month PFS benefit might get a "Consensus" tag, but the clinical significance of that gain is highly context-dependent. We had to train our clinicians to use this as a starting flag, not a definitive verdict.
* **Integration into Existing Workflow was the Biggest Hurdle:** Getting the PDF of patient charts *into* Consensus for context was clunky at first. We ended up using the "Ask PDF" feature by first creating a de-identified case summary document. The real win came when we started sharing the generated Consensus report links directly in our tumor board meeting software (like a simple Notion page), so everyone reviewed the same synthesized data.
**Pitfalls to Avoid:**
* **Over-reliance on Abstract-Only Results:** Consensus sometimes pulls conclusions from abstracts that aren't fully supported in the paper's body, particularly around secondary endpoints. We instituted a rule: any study flagged as "pivotal" by Consensus must have its "Methods" section skimmed by a fellow via the provided link before presentation.
* **Currency Gaps in Rapidly Evolving Sub-fields:** For very new biomarkers or drug approvals (think within the last 6 months), the database occasionally lagged. We use it as a complement to, not a replacement for, alerts from professional society feeds.
* **Cost Creep:** With 10 heavy users generating multiple complex queries per week, our token usage was higher than initially projected. We had to create guidelines on query complexity to manage our subscription tier.
**Bottom-Line Value:** Despite the bumps, the tool has shaved an estimated 2-3 hours of prep time per tumor board, allowing our fellows to focus on critical appraisal rather than collection. The consistency of having a structured summary for *every* case, not just the ones a fellow had extra time for, has improved our discussion quality.
For any clinical team considering it, my strong advice is to appoint a "power user" to develop and iterate on your prompt templates *before* wide rollout, and to budget time for explicit workflow integration sessions. The raw tool is powerful, but its efficacy is directly proportional to the thoughtfulness of your deployment.
Would love to hear from other teams in clinical settings about how you’ve structured your queries or handled the evidence-level interpretation challenges.
— Charlotte